Home › Non-Small Cell Lung Cancer › Ohio
Non-Small Cell Lung Cancer clinical trials in Ohio
120 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Ohio.
Cities in Ohio
- Columbus55 studies
- Cleveland43 studies
- Cincinnati35 studies
- Akron22 studies
- Toledo17 studies
- Dayton13 studies
- Youngstown5 studies
- Parma4 studies
- Zanesville4 studies
- Newark3 studies
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- University of Cincinnati Cancer Center, Cincinnati
- The Ohio State University, Columbus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 10, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0383, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361510Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cleveland Clinic Akron General, Akron
- Strecker Cancer Center-Belpre, Belpre
- Aultman Health Foundation, Canton
- and 33 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04267848A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07814248A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Akron General Medical Center, Akron
- The Christ Hospital, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361497Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- ProMedica Flower Hospital, Sylvania
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07388524Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- The Mark H Zangmeister Center /ID# 272502, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- TriHealth Cancer & Blood Institute Research, Cincinnati
- Taylor Cancer Research Center, Maumee
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Aultman Health Foundation, Canton
- Miami Valley Hospital South, Centerville
- Ohio State University Comprehensive Cancer Center, Columbus
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06498635A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- University of Cincinnati Medical Center ( Site 0119), Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06623422A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07144280Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Aultman Hospital, Canton
- Aultman Medical Group Hematology and Oncology, Canton
- Oncology Hematology Care Clinical Trials, Cincinnati
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
- University Hospitals Cleveland Medical Center, Cleveland
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Canton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Dayton Physician's Network, Dayton
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 25, 2026 · NCT05920356A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Cincinnati Veterans Affairs Medical Center, Cincinnati
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667908Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03191149Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Aultman Hospital, Canton
- Miami Valley Hospital South, Centerville
- Fairview Hospital, Cleveland
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- Gabrail Cancer Center, Canton
- Taylor Cancer Research Center, Maumee
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Cleveland
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Cincinnati
- Research Site, Maumee
- Research Site, Toledo
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Local Institution - 0102, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06618287A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0486, Centerville
- University of Cincinnati Medical Center, Cincinnati
- Local Institution - 0519, Elyria
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University Hospitals Cleveland Medical Center, Cleveland
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07100080Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Gabrail Cancer Center Research, Canton
- The Christ Hospital Cancer Center, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
- and 5 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06712316Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07104630A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Mercy Health - Perrysburg Cancer Center /ID# 270536, Perrysburg
- Genesis Healthcare System /ID# 273361, Zanesville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06568939Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Ohio State University, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06529822A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Sites, Cincinnati
- Clinical Study Site, Cleveland
- Clinical Study Sites, Columbus
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06767514A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Gabrail Cancer Center, Canton
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06855771Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- Gabrail Cancer Center Research, Canton
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04486833Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-893-B, Cincinnati
- USOR - Oncology Hematology Care - Blue Ash, Cincinnati
- Local Institution - 007-893-C, Cincinnati
- and 5 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04613596The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Gabrail Cancer Center, Canton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06899126Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04780568From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.